Not exact matches
While Tecentriq's results
in Imvigor211 were consistent with its
previous study, Roche said, patients getting chemotherapy
in the latest
trial survived longer
than anticipated.
The
study tested a lower dose of the oral multi-targeted tyrosine kinase inhibitor sunitinib
than in previous trials, where toxicity proved too much of a problem.
Our sample can be characterized as high risk (baseline ECBI T score > 55) 42 or at the borderline of clinical (T score > 60), 34 which is typical of
previous randomized clinical
trials of parent training for young children.41 The results across methods
in this
study are impressive given that effect sizes have been shown to be associated with the magnitude of symptom severity at baseline, 43 and thus it is typically more difficult to find large effects
in prevention
than in intervention
trials.